Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410Aexternal-prioritypatent/GB0019410D0/en
Priority claimed from GB0019524Aexternal-prioritypatent/GB0019524D0/en
Priority claimed from GB0019523Aexternal-prioritypatent/GB0019523D0/en
Application filed by Glaxosmithkline Lab Sas, Glaxo Group LtdfiledCriticalGlaxosmithkline Lab Sas
Publication of MY138979ApublicationCriticalpatent/MY138979A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
THE INVENTION RELATES TO THE USE OF A 5-HT... RECEPTOR ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF ATRIAL REMODELLING IN A MAMMAL. PREFERABLY, THE ANTAGONIST IS N-[(1-...butyl-4-piperidinyl)methyl]-3, 4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF. THE INVENTION ALSO RELATES TO THE USE OF SB 207266 OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OR PROPHYLAXIS OF ATRIAL FIBRILLATION IN A MAMMAL BY ADMINISTERING TO THE MAMMAL A DAILY ORAL OR PARENTERAL DOSAGE REGIMEN OF ABOUT 0.2 mg TO 1.0 mg OF THE SB 207266 OR SALT THEREOF PER kg OF TOTAL BODY WEIGHT (MEASURED AS THE FREE BASE).
MYPI200137032000-08-072001-08-07The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
MY138979A
(en)
4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use for preparation of pharmaceutical compositions
Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them